Asosiy kontentga oʻtish
Maqola

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

Juan‐José GarcésClinica Universidad de NavarraMaría‐Teresa CedenaHospital Universitario 12 de Octubre, Madrid, SpainNoemí PuigHospital Universitario de Salamanca, Salamanca, SpainLeire BurgosClinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Navarra, SpainJosé J. PérezHospital Universitario de Salamanca, Salamanca, SpainLourdes CordónGrupo de Investigación en Hematología, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, SpainJuan Flores‐MonteroDepartment of Medicine, University of Salamanca (USAL) and CIBERONC, Salamanca, SpainLuzalba Sanoja-FloresHospital Universitario Virgen del RocíoMarı́a José CalasanzClinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Navarra, SpainAlbert OrtiolInstitut Català d'Oncologia L'Hospitalet, Barcelona, SpainMaría‐Jesús BlanchardHospital Ramón y Cajal, Madrid, SpainRafael RíosHospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, SpainJesús MartínHospital Universitario Virgen del RocíoRafael Martínez-MartinezHospital Universitario San Carlos, Madrid, SpainJoan BargayHospital Universitario Son Llatzer, Institut d' Investigacio Illes Balears (IdISBa), Palma de Mallorca, SpainAnna SuredaInstitut Català d'Oncologia L'Hospitalet, Barcelona, SpainJavier de la RubiaInstituto de Investigación Sanitaria La FeMiguel-Teodoro HernandezHospital Universitario de Canarias, Santa Cruz de Tenerife, SpainPaula Rodríguez‐OteroClinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Navarra, SpainJavier de la CruzHospital Universitario 12 de Octubre, Madrid, SpainAlberto ÓrfãoCentro de Investigación del CáncerMaría‐Victoria MateosHospital Universitario de Salamanca, Salamanca, SpainJoaquín Martínez‐LópezHospital Universitario 12 de Octubre, Madrid, SpainJuan José LahuertaHospital Universitario 12 de Octubre, Madrid, SpainLaura RosiñolHospital Clínic, IDIBAPS, Barcelona, SpainJoan BladéHospital Clínic, IDIBAPS, Barcelona, SpainJesús F. San MiguelClinica Universidad de NavarraBruno PaivaClinica Universidad de Navarra
2022en
ABI

Annotatsiya

PURPOSE Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells (PCs) continues to be performed in BM since the clinical translation of circulating tumor cells (CTCs) remains undefined. PATIENTS AND METHODS CTCs were measured in peripheral blood (PB) of 374 patients with newly diagnosed MM enrolled in the GEM2012MENOS65 and GEM2014MAIN trials. Treatment included bortezomib, lenalidomide, and dexamethasone induction followed by autologous transplant, consolidation, and maintenance. Next-generation flow cytometry was used to evaluate CTCs in PB at diagnosis and measurable residual disease (MRD) in BM throughout treatment. RESULTS CTCs were detected in 92% (344 of 374) of patients with newly diagnosed MM. The correlation between the percentages of CTCs and BM PCs was modest. Increasing logarithmic percentages of CTCs were associated with inferior progression-free survival (PFS). A cutoff of 0.01% CTCs showed an independent prognostic value (hazard ratio: 2.02; 95% CI, 1.3 to 3.1; P = .001) in multivariable PFS analysis including the International Staging System, lactate dehydrogenase levels, and cytogenetics. The combination of the four prognostic factors significantly improved risk stratification. Outcomes according to the percentage of CTCs and depth of response to treatment showed that patients with undetectable CTCs had exceptional PFS regardless of complete remission and MRD status. In all other cases with detectable CTCs, only achieving MRD negativity (and not complete remission) demonstrated a statistically significant increase in PFS. CONCLUSION Evaluation of CTCs in PB outperformed quantification of BM PCs. The detection of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible MM.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba